139 related articles for article (PubMed ID: 15812066)
1. FDA Oncology Committee debates Iressa's status following negative trial results.
Twombly R
J Natl Cancer Inst; 2005 Apr; 97(7):473. PubMed ID: 15812066
[No Abstract] [Full Text] [Related]
2. Gefitinib does not increase survival in lung cancer patients.
Golsteyn RM
Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
[No Abstract] [Full Text] [Related]
3. Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Twombly R
J Natl Cancer Inst; 2005 Feb; 97(4):249-50. PubMed ID: 15713955
[No Abstract] [Full Text] [Related]
4. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Friedrich MJ
J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
[No Abstract] [Full Text] [Related]
5. Iressa's fall from grace points to need for better clinical trials.
Singer E
Nat Med; 2005 Feb; 11(2):107. PubMed ID: 15692580
[No Abstract] [Full Text] [Related]
6. FDA announces fast track approval of new drug for lung cancer.
Dyer O
BMJ; 2003 May; 326(7397):1004. PubMed ID: 12742913
[No Abstract] [Full Text] [Related]
7. Cancer drugs. Smart weapons prove tough to design.
Couzin J
Science; 2002 Oct; 298(5593):522-5. PubMed ID: 12386312
[No Abstract] [Full Text] [Related]
8. More haste, less speed.
Lancet Oncol; 2003 Jun; 4(6):325. PubMed ID: 12788389
[No Abstract] [Full Text] [Related]
9. Keeping pace with innovation.
Lancet Oncol; 2005 Feb; 6(2):65. PubMed ID: 15683813
[No Abstract] [Full Text] [Related]
10. FDA approves new drug for specific type of advanced breast cancer.
Mayo Clin Womens Healthsource; 2007 Oct; 11(10):3. PubMed ID: 18418907
[No Abstract] [Full Text] [Related]
11. Selection bias, phase II trials, and the FDA accelerated approval process.
George SL
J Natl Cancer Inst; 2003 Sep; 95(18):1351-2. PubMed ID: 13130101
[No Abstract] [Full Text] [Related]
12. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
[TBL] [Abstract][Full Text] [Related]
13. Conflicting signals on US accelerated approvals.
Fox JL
Nat Biotechnol; 2005 Sep; 23(9):1027-8. PubMed ID: 16151377
[No Abstract] [Full Text] [Related]
14. Clinical trial of Iressa.
FDA Consum; 2005; 39(2):4. PubMed ID: 16121415
[No Abstract] [Full Text] [Related]
15. Should the FDA be the doctor of last resort?
DeVita VT
Nat Clin Pract Oncol; 2005 Sep; 2(9):423. PubMed ID: 16264991
[No Abstract] [Full Text] [Related]
16. Despite concerns, FDA panel backs EGFR inhibitor.
Twombly R
J Natl Cancer Inst; 2002 Nov; 94(21):1596-7. PubMed ID: 12419780
[No Abstract] [Full Text] [Related]
17. Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC.
Expert Rev Anticancer Ther; 2003 Jun; 3(3):257. PubMed ID: 12820770
[No Abstract] [Full Text] [Related]
18. Accelerated approval scrutinized: confirmatory phase 4 studies on new drugs languish.
Mitka M
JAMA; 2003 Jun; 289(24):3227-9. PubMed ID: 12824196
[No Abstract] [Full Text] [Related]
19. Patient group seeks overhaul of FDA clinical trial system in court.
Hede K
J Natl Cancer Inst; 2006 Sep; 98(18):1268-70. PubMed ID: 16985242
[No Abstract] [Full Text] [Related]
20. Cancer medicine hits a target.
Sobel RK
US News World Rep; 2002 Jun; 132(19):54. PubMed ID: 12066454
[No Abstract] [Full Text] [Related]
[Next] [New Search]
